COLL - Collegium Pharmaceutical: Moving Closer To The Top

• Collegium Pharmaceutical continues to move closer to achieving their mission of becoming the market leader in responsible pain management. Collegium reported a strong beat on their Q1 EPS and revenue.
• Xtampza ER is rapidly accruing market share and record all-time highs in total prescriptions, new-to-brand, and market share, and total prescribers in the quarter.
• The company continues to report substantial year-over-year and sequential growth in key financial and commercial metrics. As a result, I believe COLL is worth a long-term investment.

For further details see: